Which has higher earnings and valuation, KZIA or ACRV?

Novogen has higher revenue and earnings than Acrivon Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 668.80 -$13.41M N/A N/A Acrivon Therapeutics N/A N/A -$77.90M -$1.88 N/A

Is KZIA or ACRV more profitable?

Novogen's return on equity of 0.00% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Acrivon Therapeutics N/A -70.14% -61.60%

Does the media favor KZIA or ACRV?

In the previous week, Novogen had 5 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 8 mentions for Novogen and 3 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.63 beat Novogen's score of 0.20 indicating that Acrivon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Acrivon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RLYB or KZIA?

Novogen has a consensus target price of $27.33, suggesting a potential upside of 124.78%. Given Novogen's stronger consensus rating and higher probable upside, analysts plainly believe Novogen is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Novogen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has better valuation & earnings, RLYB or KZIA?

Rallybio has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rallybio $860K 104.22 -$8.98M -$4.34 N/A Novogen $30K 668.80 -$13.41M N/A N/A

Is RLYB or KZIA more profitable?

Novogen has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Novogen's return on equity of 0.00% beat Rallybio's return on equity. Company Net Margins Return on Equity Return on Assets Rallybio -911.07% -40.53% -38.13% Novogen N/A N/A N/A

Does the media prefer RLYB or KZIA?

In the previous week, Novogen had 7 more articles in the media than Rallybio. MarketBeat recorded 8 mentions for Novogen and 1 mentions for Rallybio. Rallybio's average media sentiment score of 1.51 beat Novogen's score of 0.20 indicating that Rallybio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Novogen 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, KZIA or SERA?

Novogen has higher earnings, but lower revenue than Sera Prognostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 668.80 -$13.41M N/A N/A Sera Prognostics $80K 976.39 -$31.93M -$0.67 N/A

Does the media favor KZIA or SERA?

In the previous week, Novogen had 7 more articles in the media than Sera Prognostics. MarketBeat recorded 8 mentions for Novogen and 1 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.59 beat Novogen's score of 0.20 indicating that Sera Prognostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sera Prognostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ACET or KZIA?

Novogen has higher revenue and earnings than Adicet Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adicet Bio N/A N/A -$116.80M -$11.45 N/A Novogen $30K 668.80 -$13.41M N/A N/A

Is ACET or KZIA more profitable?

Novogen's return on equity of 0.00% beat Adicet Bio's return on equity. Company Net Margins Return on Equity Return on Assets Adicet Bio N/A -74.90% -60.87% Novogen N/A N/A N/A

Does the media prefer ACET or KZIA?

In the previous week, Novogen had 2 more articles in the media than Adicet Bio. MarketBeat recorded 8 mentions for Novogen and 6 mentions for Adicet Bio. Adicet Bio's average media sentiment score of 0.57 beat Novogen's score of 0.20 indicating that Adicet Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adicet Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Novogen 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, OKYO or KZIA?

OKYO Pharma has higher earnings, but lower revenue than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$8.95M N/A N/A Novogen $30K 668.80 -$13.41M N/A N/A

Is OKYO or KZIA more profitable?

Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A Novogen N/A N/A N/A

Does the media favor OKYO or KZIA?

In the previous week, Novogen had 7 more articles in the media than OKYO Pharma. MarketBeat recorded 8 mentions for Novogen and 1 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 1.89 beat Novogen's score of 0.20 indicating that OKYO Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OKYO Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Novogen 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Novogen (KZIA) Competitors

$12.16 -0.45 (-3.57%)

As of 09/3/2026 04:00 PM Eastern

Compare

KZIA vs. ACRV, RLYB, SERA, ACET, and OKYO

Should you buy Novogen stock or one of its competitors? Novogen's main competitors and comparable companies include Acrivon Therapeutics (ACRV), Rallybio (RLYB), Sera Prognostics (SERA), Adicet Bio (ACET), and OKYO Pharma (OKYO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Novogen compare to Acrivon Therapeutics?

Novogen (NASDAQ:KZIA) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

30.9% of Novogen shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Novogen has higher revenue and earnings than Acrivon Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	668.80	-$13.41M	N/A	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A

In the previous week, Novogen had 5 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 8 mentions for Novogen and 3 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.63 beat Novogen's score of 0.20 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acrivon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novogen's return on equity of 0.00% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Acrivon Therapeutics	N/A	-70.14%	-61.60%

Novogen presently has a consensus target price of $27.33, indicating a potential upside of 124.78%. Acrivon Therapeutics has a consensus target price of $13.50, indicating a potential upside of 555.34%. Given Acrivon Therapeutics' higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Novogen has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

Summary

Novogen beats Acrivon Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Novogen compare to Rallybio?

Rallybio (NASDAQ:RLYB) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

90.3% of Rallybio shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 10.3% of Rallybio shares are held by company insiders. Comparatively, 1.0% of Novogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Novogen had 7 more articles in the media than Rallybio. MarketBeat recorded 8 mentions for Novogen and 1 mentions for Rallybio. Rallybio's average media sentiment score of 1.51 beat Novogen's score of 0.20 indicating that Rallybio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Novogen	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rallybio has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	104.22	-$8.98M	-$4.34	N/A
Novogen	$30K	668.80	-$13.41M	N/A	N/A

Novogen has a consensus target price of $27.33, suggesting a potential upside of 124.78%. Given Novogen's stronger consensus rating and higher probable upside, analysts plainly believe Novogen is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Novogen has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Novogen's return on equity of 0.00% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-40.53%	-38.13%
Novogen	N/A	N/A	N/A

Rallybio has a beta of -0.85, indicating that its share price is 185% less volatile than the broader market. Comparatively, Novogen has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market.

Summary

Novogen beats Rallybio on 9 of the 14 factors compared between the two stocks.

How does Novogen compare to Sera Prognostics?

Novogen (NASDAQ:KZIA) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Novogen currently has a consensus price target of $27.33, suggesting a potential upside of 124.78%. Sera Prognostics has a consensus price target of $5.50, suggesting a potential upside of 177.78%. Given Sera Prognostics' higher possible upside, analysts clearly believe Sera Prognostics is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Novogen has higher earnings, but lower revenue than Sera Prognostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	668.80	-$13.41M	N/A	N/A
Sera Prognostics	$80K	976.39	-$31.93M	-$0.67	N/A

In the previous week, Novogen had 7 more articles in the media than Sera Prognostics. MarketBeat recorded 8 mentions for Novogen and 1 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.59 beat Novogen's score of 0.20 indicating that Sera Prognostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sera Prognostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

30.9% of Novogen shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 1.0% of Novogen shares are owned by company insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Novogen has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Novogen's return on equity of 0.00% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Novogen has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

Summary

Novogen beats Sera Prognostics on 8 of the 15 factors compared between the two stocks.

How does Novogen compare to Adicet Bio?

Adicet Bio (NASDAQ:ACET) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

In the previous week, Novogen had 2 more articles in the media than Adicet Bio. MarketBeat recorded 8 mentions for Novogen and 6 mentions for Adicet Bio. Adicet Bio's average media sentiment score of 0.57 beat Novogen's score of 0.20 indicating that Adicet Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adicet Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Novogen	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novogen's return on equity of 0.00% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adicet Bio	N/A	-74.90%	-60.87%
Novogen	N/A	N/A	N/A

Novogen has higher revenue and earnings than Adicet Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A
Novogen	$30K	668.80	-$13.41M	N/A	N/A

Adicet Bio currently has a consensus price target of $46.80, suggesting a potential upside of 396.29%. Novogen has a consensus price target of $27.33, suggesting a potential upside of 124.78%. Given Adicet Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Adicet Bio is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Adicet Bio has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, Novogen has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

83.9% of Adicet Bio shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 3.4% of Adicet Bio shares are held by insiders. Comparatively, 1.0% of Novogen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Novogen beats Adicet Bio on 7 of the 13 factors compared between the two stocks.

How does Novogen compare to OKYO Pharma?

OKYO Pharma (NASDAQ:OKYO) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Novogen	N/A	N/A	N/A

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 1.0% of Novogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

OKYO Pharma has higher earnings, but lower revenue than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A
Novogen	$30K	668.80	-$13.41M	N/A	N/A

OKYO Pharma has a beta of 0.03, suggesting that its stock price is 97% less volatile than the broader market. Comparatively, Novogen has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

In the previous week, Novogen had 7 more articles in the media than OKYO Pharma. MarketBeat recorded 8 mentions for Novogen and 1 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 1.89 beat Novogen's score of 0.20 indicating that OKYO Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OKYO Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Novogen	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

OKYO Pharma currently has a consensus price target of $5.67, suggesting a potential upside of 265.59%. Novogen has a consensus price target of $27.33, suggesting a potential upside of 124.78%. Given OKYO Pharma's higher possible upside, equities analysts plainly believe OKYO Pharma is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Novogen beats OKYO Pharma on 6 of the 10 factors compared between the two stocks.

Get Novogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KZIA vs. The Competition

Export

Metric	Novogen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$20.85M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	N/A	12.66	273.29	25.38
Price / Sales	668.80	1,309.08	613.45	97.56
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	-2.28	16.29	12.89	6.14
Net Income	-$13.41M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-10.46%	0.34%	0.60%	-0.27%
1 Month Performance	-1.22%	8.52%	5.73%	0.68%
1 Year Performance	50.31%	52.66%	25.35%	14.84%

Novogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KZIA Novogen	4.3306 of 5 stars	$12.16 -3.6%	$27.33 +124.8%	+51.4%	$20.85M	$30K	N/A	12	Analyst Forecast
ACRV Acrivon Therapeutics	3.159 of 5 stars	$2.12 -3.0%	$13.50 +538.3%	+53.7%	$90.63M	N/A	N/A	58	Analyst Upgrade
RLYB Rallybio	1.7082 of 5 stars	$16.85 -0.3%	N/A	+265.4%	$89.45M	$860K	N/A	40	Positive News
SERA Sera Prognostics	2.5701 of 5 stars	$2.16 -0.9%	$5.50 +154.5%	-41.8%	$85.25M	$80K	N/A	120
ACET Adicet Bio	3.9556 of 5 stars	$8.81 -2.1%	$46.80 +431.3%	-19.3%	$82.12M	N/A	N/A	90	News Coverage Analyst Upgrade Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KZIA) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novogen (KZIA) Competitors

KZIA vs. ACRV, RLYB, SERA, ACET, and OKYO

How does Novogen compare to Acrivon Therapeutics?

Summary

How does Novogen compare to Rallybio?

Summary

How does Novogen compare to Sera Prognostics?

Summary

How does Novogen compare to Adicet Bio?

Summary

How does Novogen compare to OKYO Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novogen (KZIA) Competitors

KZIA vs. ACRV, RLYB, SERA, ACET, and OKYO

How does Novogen compare to Acrivon Therapeutics?

Do institutionals & insiders have more ownership in KZIA or ACRV?

Which has higher earnings and valuation, KZIA or ACRV?

Does the media favor KZIA or ACRV?

Is KZIA or ACRV more profitable?

Do analysts prefer KZIA or ACRV?

Which has more volatility and risk, KZIA or ACRV?

Summary

How does Novogen compare to Rallybio?

Do institutionals and insiders hold more shares of RLYB or KZIA?

Does the media prefer RLYB or KZIA?

Which has better valuation & earnings, RLYB or KZIA?

Do analysts prefer RLYB or KZIA?

Is RLYB or KZIA more profitable?

Which has more risk and volatility, RLYB or KZIA?

Summary

How does Novogen compare to Sera Prognostics?

Do analysts recommend KZIA or SERA?

Which has preferable earnings & valuation, KZIA or SERA?

Does the media favor KZIA or SERA?

Do institutionals & insiders hold more shares of KZIA or SERA?

Is KZIA or SERA more profitable?

Which has more volatility & risk, KZIA or SERA?

Summary

How does Novogen compare to Adicet Bio?

Does the media prefer ACET or KZIA?

Is ACET or KZIA more profitable?

Which has preferable valuation & earnings, ACET or KZIA?

Do analysts recommend ACET or KZIA?

Which has more volatility and risk, ACET or KZIA?

Do institutionals and insiders hold more shares of ACET or KZIA?

Summary

How does Novogen compare to OKYO Pharma?

Is OKYO or KZIA more profitable?

Do insiders & institutionals hold more shares of OKYO or KZIA?

Which has better valuation and earnings, OKYO or KZIA?

Which has more volatility & risk, OKYO or KZIA?

Does the media favor OKYO or KZIA?

Do analysts recommend OKYO or KZIA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools